IDYA — Ideaya Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $3.13bn
- $2.60bn
- $23.39m
- 37
- 12
- 94
- 45
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 19.5 | 27.9 | 50.9 | 23.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 44.3 | 54.9 | 78.2 | 113 | 158 |
Operating Profit | -44.3 | -35.3 | -50.3 | -62.5 | -134 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -42 | -34.5 | -49.8 | -58.7 | -113 |
Net Income After Taxes | -42 | -34.5 | -49.8 | -58.7 | -113 |
Net Income Before Extraordinary Items | |||||
Net Income | -42 | -34.5 | -49.8 | -58.7 | -113 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -42 | -34.5 | -49.8 | -58.7 | -113 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.36 | -1.4 | -1.41 | -1.42 | -1.96 |